What is cabozantinib and how much does it cost?

Cabozantinib (Cabozantinib), also known as XL184, is a multi-target small molecule tyrosine kinase inhibitor developed by Exelixis Biopharmaceutical Company and is widely used to treat a variety of malignant tumors worldwide. Cabozantinib has demonstrated remarkable effects in cancer treatment with its unique multi-target mechanism of action and has become a new hope for many cancer patients.

Cabozantinib is available in two main forms for clinical use:

Capsule dosage form (Cometriq): mainly used to treat medullary thyroid cancer. This form of cabozantinib effectively blocks the proliferation and spread of tumor cells by inhibiting multiple tyrosine kinase targets related to tumor growth, angiogenesis and metastasis, such as RET, VEGFR, etc., thereby controlling disease progression.

Tablet form (Cabometyx): It is mainly used to treat renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancer. Tablet cabozantinib also exerts anti-tumor effects through its multi-target inhibitory effect, targeting specific gene mutations or signaling pathway abnormalities in these cancers. Its clinical application shows that it has significant advantages in prolonging the survival period of patients and improving the quality of life.

Cabozantinib is widely recognized for its therapeutic efficacy in a variety of cancers. For example, in the treatment of renal cell carcinoma and hepatocellular carcinoma, cabozantinib, as a second- or third-line treatment, can significantly extend the progression-free survival and overall survival of patients. At the same time, cabozantinib also shows good control effect on bone metastasis, providing a new treatment option for cancer patients with bone metastasis.

However, cabozantinib may also cause some side effects during use, such as diarrhea, fatigue, hypertension, hand-foot syndrome, etc. Therefore, when using cabozantinib, doctors will develop an individualized treatment plan based on the patient's specific situation and closely monitor the patient's response and side effects to ensure the safety and effectiveness of the treatment.

Cabozantinib is not currently on the market in China. Therefore, patients in need cannot purchase it directly from domestic hospitals. It is understood that cabozantinib has original research versions and multiple generic versions available overseas. The price of the original research version of tablets is approximatelyThe price is about 35,000 yuan, while the price of capsules is about 46,000 yuan. Among them, the original research version of tablets produced in Türkiye has outstanding performance in terms of cost performance. In addition, the generic versions of cabozantinib available overseas, whether in capsules or tablets, are relatively affordable, ranging from RMB 800 to RMB 7,600, providing patients with more choices. If patients have more questions about cabozantinib, please consult a regular overseas medical consulting company for more information.

Cabozantinib, as a multi-target small molecule tyrosine kinase inhibitor, plays an important role in the treatment of medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma and other cancers. Its unique multi-target mechanism of action and significant therapeutic effects provide patients with new treatment options and hope. However, it is also necessary to pay attention to its potential side effects and safety issues when using cabozantinib to ensure the smooth progress of the treatment process.